ADMA Biologics (NASDAQ:ADMA) Stock Price Up 5.3% - Here's Why

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) were up 5.3% during mid-day trading on Wednesday . The stock traded as high as $22.18 and last traded at $21.96. Approximately 776,143 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 3,648,315 shares. The stock had previously closed at $20.86.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James lifted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Trading Down 3.7%

The business's 50-day moving average price is $20.94 and its 200 day moving average price is $18.87. The company has a market cap of $4.97 billion, a P/E ratio of 74.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business's revenue was up 40.2% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. As a group, analysts expect that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director now owns 478,194 shares in the company, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total transaction of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares of the company's stock, valued at $2,333,345.60. This trade represents a 6.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,000 shares of company stock valued at $814,936. Company insiders own 3.50% of the company's stock.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Skandinaviska Enskilda Banken AB publ acquired a new stake in ADMA Biologics in the 1st quarter worth about $35,000. SVB Wealth LLC acquired a new stake in ADMA Biologics in the 1st quarter worth about $35,000. Mark Sheptoff Financial Planning LLC acquired a new stake in ADMA Biologics in the 4th quarter worth about $35,000. Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares in the last quarter. Finally, Tsfg LLC acquired a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $51,000. Institutional investors and hedge funds own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.